Abstract 2156
Background
The mobile application is a valuable tool in the transmission of information in terms of having easy access in our daily lives and hosting applications containing information specific to many diseases. After breast cancer surgery, the patients are generally preferred to have verbal expressions in their education. In this context, it is considered that mobile application is the right choice in order to provide the opportunity for the patients to manage their post-operative processes, to facilitate their access to the right information and to provide a positive contribution to their quality of life by providing consultancy services.
Methods
The text content of the mobile application has text, image, video and audio equipment as well as online support / consulting services. It is thought that the mobile application will have a separate interface for each problem, and text and animation content will be the only problem for each interface. Care was taken to ensure that the created interfaces were of different colors and the layout to be used for problem solving was similar for each interface. It was ensured that the patients were checked from the admin panel if they did not watch or watch the videos again. All these operations were entered by entering the user name and password and recorded by end-to-end encryption.
Results
Supporting self-care for a woman who has not yet achieved her responsibility to cope with all responsibilities will contribute to the maintenance of family unity. In the creation of a mobile application that can be reached continuously; It is aimed to support self-care, create a tool that can receive support without any social isolation, decrease individual dependence and increase self-esteem. Thus, the fact that the woman does not have to spend the post-operative period at home and can be used individually and at the desired time constitutes the other advantages of the mobile application.
Conclusions
If the patient with breast surgery has an equipment to support self-care in the post-operative home, it will be possible to decrease the rate of experiencing physiological, psychological and sociological problems. It will be possible for the patient who has no problems to decrease their applications to the hospital and to contribute to the economy of the country.
Clinical trial identification
Legal entity responsible for the study
Aydanur Aydin.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3212 - Multigene panel testing results for hereditary breast cancer in 1325 individuals: implications for gene selection and considerations for guidelines.
Presenter: Georgios Tsaousis
Session: Poster Display session 3
Resources:
Abstract
2591 - PIK3R5 genetic predictors of hypertension induced by VEGF-pathway inhibitors
Presenter: Julia Quintanilha
Session: Poster Display session 3
Resources:
Abstract
4377 - ERBB2 mRNA as a predictor in HER2-positive (HER2+)/hormone receptor-positive (HR+) metastatic breast cancer (BC) treated with HER2 blockade in combination with endocrine therapy (ET): a retrospective analysis of the ALTERNATIVE and SOLTI-PAMELA trials.
Presenter: Nuria Chic
Session: Poster Display session 3
Resources:
Abstract
3439 - Early on-treatment vs pre-treatment tumor transcriptomes as predictors of response to neoadjuvant therapy for HER2-positive inflammatory breast cancer
Presenter: Sonia Pernas
Session: Poster Display session 3
Resources:
Abstract
2512 - AXL expression predicts poor prognosis and lack of efficacy of anti-angiogenic and anti-epidermal growth factor receptor (EGFR) agents in patients (pts) with RAS wild type (WT) metastatic colorectal cancer (mCRC)
Presenter: Claudia Cardone
Session: Poster Display session 3
Resources:
Abstract
4061 - Prevalence of EGFR mutations and its correlation with Egyptian patients’ human kinetics (PEEK Study)
Presenter: Adel Ibrahim
Session: Poster Display session 3
Resources:
Abstract
2547 - Evaluation of tumor microenvironment identifies immune correlates of response to combination immunotherapy with margetuximab (M) and pembrolizumab (P) in HER2+ gastroesophageal adenocarcinoma (GEA)
Presenter: Sergio Rutella
Session: Poster Display session 3
Resources:
Abstract
4671 - Clinicopathological and molecular criteria assessment for the screening of hypermutated proficient mismatch repair (pMMR) colorectal cancers (CRC) with exonucleasic domain POLE (edPOLE) mutations (mt).
Presenter: Benoit Rousseau
Session: Poster Display session 3
Resources:
Abstract
3862 - Tumor mutation burden and microsatellite instability in colorectal cancer
Presenter: Francesca Fenizia
Session: Poster Display session 3
Resources:
Abstract
4614 - Predictors of Response to Checkpoint Inhibitors in Naïve and Ipilimumab-Refractory Melanoma
Presenter: Domenico Mallardo
Session: Poster Display session 3
Resources:
Abstract